Pfenex (PFNX) Tops Q2 EPS by 4c
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- AMC Entertainment (AMC) Enters $250M ATM Agreement
Pfenex (PFNX) Announces Positive Results for Px563L Anthrax Vaccine Study
August 8, 2016 7:32 AM EDTPfenex Inc. (NYSE: PFNX) announced positive immunogenicity and safety data from the Day 70 analysis of the Px563L anthrax vaccine study. The results demonstrate tolerable safety and significant immunogenicity after only 2 doses of Px563L.
"The Px563L data from the Day 70 analysis of the phase 1 study are very encouraging, with the vaccine being well-tolerated and affording potentially superior protection after only 2 doses," noted Dr. Hubert Chen, chief medical officer of Pfenex. Bertrand C. Liang, chief executive officer added, "These positive anthrax vaccine findings are a strong validation of our close... More
Pfenex (PFNX) Will Regain Full Rights to Lucentis Biosimilar PF582
August 8, 2016 7:31 AM EDTPfenex Inc. (NYSE : PFNX) announced that the company will regain the full rights to PF582, a biosimilar candidate to Lucentis, following our partner's strategic review of the current therapeutic focus of its biosimilar pipeline.
"With Pfenex regaining the rights to PF582 we are announcing the PF582 phase 1/2 safety and efficacy data which we believe highlights the significant value of the program," stated Bertrand C. Liang, chief executive officer of Pfenex. "We will consider strategic... More